Exelixis Prepares Zanzalintinib Launch; CABOMETYX NET Ramp Under Scrutiny

What happened

Exelixis executives recently outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib (zanza) in colorectal cancer later this year, signaling a push toward a dual-franchise model. The news arrives as the company's core CABOMETYX business faces a ramp hurdle in the newly approved NET indication, which could temper growth expectations despite its strong RCC share. Management's commentary aligns with earlier guidance that excludes any zanzalintinib revenue from 2026 forecasts, keeping the launch as pure option value. The latest master report rates the stock WAIT with a price around $44, a P/E of 17, and limited margin of safety after a 28% 12-month gain, reflecting a crowded, well-owned position. Key near-term catalysts include FDA acceptance of the zanzalintinib NDA and topline STELLAR-304 data in non-clear cell RCC, both of which will determine whether the second franchise de-risks on schedule.

Implication

The blend of news and master report suggests the stock remains fairly valued at ~$44, with near-term upside contingent on above-guidance Cabometyx durability and clean zanzalintinib approval. The NET ramp hurdle flagged in the news could signal slower-than-expected uptake in that indication, which would shift revenue growth toward the lower end of guidance. Conversely, a smooth zanza launch would accelerate the transition to a dual-franchise model and justify a higher multiple, but that outcome is not yet de-risked. Given the crowded positioning and structural risks, we maintain a WAIT stance with attractive entry at $38 and trim above $52, reassessing within 6-12 months as key catalysts play out. Investors should avoid chasing strength and instead wait for either a pullback or clearer evidence of an operational beat.

Thesis delta

The core thesis remains intact but with a marginal negative adjustment due to the reported NET ramp hurdle. While zanza launch preparations are positive, the potential slower NET uptake could weigh on near-term CABOMETYX growth versus earlier projections. We maintain our WAIT rating and entry/targets, but monitor NET prescription data as a potential early warning of revenue deceleration.